Modulation of inflammation and immunity by arginine supplements

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 1, Issue 6, 1998, Pages 531-538

  Efron, David T ^a   Barbul, Adrian ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL; DIET SUPPLEMENTATION; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; PHYSIOLOGY; REVIEW; WOUND HEALING;

ANIMALS; ARGININE; DIETARY SUPPLEMENTS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; WOUND HEALING;

EID: 0032199313     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199811000-00010     Document Type: Article

References (77)

1. Rose WC. The nutritive significance of the amino acids and certain related compounds. Science 1937; 86:298-300.
2. Barbul A. Arginine and immune function. Nutrition 1990; 6:53-62.
3. Seifter E, Rettura G, Barbul A, Leneson SM. Arginine: an essential amino acid for injured rats. Surgery 1978; 84:224-230.
4. Kilberg M, Stevens B, Novak D. Recent advances in mammalian amino acid transport. Annu Rev Nutr 1993; 13:137-165.
5. Fahey JL. Toxicity and blood ammonia rise resulting from intravenous amino acid administration in man: the protective effect of L-arginine. J Clin Invest 1957; 36:1647-1655.
6. Nathan C, Xie Q. Nitric oxide synthases: rolls tolls and controls. Cell 1994; 78:915-918.
7. Xia Y, Zweier J. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci U S A 1997; 94:6954-6958.
8. Beckman J, Beckman T, Chen J, Marshall P, Freeman B. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990; 87:1620-1624.
9. Parratt J. Nitric oxide in sepsis and endotoxemia. J Antimicrob Chem 1998; 41 (Suppl A):31-39. This is a comprehensive review of the clinical effects of nitric oxide in sepsis. The article provides a good summary of the available clinical data.
10. Cohen R, Huberfeld S, Genovese J, Steinberg H, Scharf S. A comparison between the acute effects of nitric oxide synthase inhibition and fluid resuscitation on myocardial function and metabolism in endotoxemic dogs. J Crit Care 1996; 11:27-36.
11. Wolfe T, Dasta J. Use of nitric oxide synthase inhibitors as a novel treatment for septic shock. Ann Pharmacother 1995; 29:36-46.
12. Wei X, Charles I, Smith A, Ure J, Feng G, Huang F, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375:408-411.
13. Meldrum D, McIntyre R Jr, Sheridan B, Cleveland J Jr, Fullerton D, Harken A. L-arginine decreases alveolar macrophage proinflammatory monokine production during acute lung injury by a nitric oxide synthase-dependent mechansim. J Trauma 1997; 34:888-893. Tumor necrosis factor α and interleukin-1β production is depressed in lung macrophages when exposed to excess arginine.
14. Madden H, Breslin R, Wasserkrug H, Efron G, Barbul A. Stimulation of T cell immunity by arginine enhances survival in peritonitis. J Surg Res 1988; 44:658-663.
15. Middleton S, Shorthouse M, Hunter J. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993; 341:465-466.
16. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, et al. Increased expression of an inducible isofrom of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with ulcerative colitis. Gut 1998; 42:180-187. This study correlates the degree of colonic mucosal injury with nitric oxide and peroxynitrite production in ulcerative colitis.
17. Vos T, Gouw A, Klok P, Havinga R, Van Goor H, Huitema S, et al. Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology 1997; 113:1323-1333. This work describes the localization of hepatic injury in lipopolysaccharide treated rats.
18. Ridger V, Pettipher E, Bryant C, Brain S. Effect of the inducible nitric oxide synthase inhibitors aminoguanidine and L-N6-(1-iminoethyl)lysine on zymosan-induced plasma extravasation in rat skin. J Immunol 1997; 159:383-390. In addition to demonstrating a role for iNOS in zymosan induced inflammation in a skin model, this paper also suggests that the effects seen are independent of the cyclooxygenase pathway.
19. Cuzzocrea S, Filippelli A, Zingarelli B, Falaciani M, Caputi A, Rossi F. Role of nitric oxide in a non septic shock model induced by zymosan in the rat. Shock 1997; 7:351-357. The deleterious systemic effects of zymosan induced peritonitis can be attenuated by pre-treatment with iNOS inhibitors.
20. Moilanen E, Moilanen T, Knowles R, Charles I, Kadoya Y, Al-Saffar N. Nitric oxide synthase is expressed in human macrophages during foreign body inflammation. Am J Pathol 1997; 150:881-887. An interesting study showing iNOS expression in granulomatous foreign body reaction in tissue adjacent to failed orthopedic prostheses. The data suggest a contributory cause of the failure may be linked to the expression of iNOS.
21. Schaffer M, Tantry U, vanWesep R, Barbul A. Nitric oxide metabolism in wounds. J Surg Res 1997; 71:25-31.
22. Shearer J, Richards J, Mills C, Caldwell M. Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am J Physiol 1997; 272:E181-E190. The authors provide a compelling proposal for the metabolism of arginine in the healing wound.
23. Paulsen S, Wurster S, Nanney L. Expression of inducible nitric oxide synthase in human burn wounds. Wound Rep Reg 1998; 6:142-148.
24. Papapetropoulus A, Desai K, Rudic R, Mayer B, Zhang R, Ruis-Torres M, et al. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-b1-stimulated capillary organization in vitro. Am J Pathol 1997; 150:1835-1844.
25. Papapetropoulus A, Garcia-Cardena G, Madri J, Sessa W. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100:3131-3139.
26. Ziche M, Morbidelli L, Masini E, Amerini S, Granger H, Maggi C, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94:2036-2044.
27. Ziche M, Morbidelli L, Choudhuri R, Zhang H, Donnini S, Granger H, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99:2625-2634.
28. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101:2567-2578.
29. Yamasaki K, Edington H, McClosky C, Tzeng E, Lizonova A, Kovesdi I, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998; 101:967-971. This work shows that the absence of the iNOS gene (in knockout mice) is accompanied by a lengthened wound healing time in excisional wounds and that the effect can be eliminated by transfer of the gene back to the tissues via an adenoviral vector.
30. Sonoki T, Nagasaki A, Gotoh T, Takiguchi M, Takeya M, Matsuzaki H, Mori M. Coinduction of nitric oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. J Biol Chem 1997; 272:3689-3693. The arginase/iNOS juxtaposition appears to be quite important. The induction and activity of each enzyme is closely linked in macrophages and both are induced with similar stimuli. Understanding this relationship will be a key to defining the net effect that arginine has in a given inflammatory milieu.
31. Ulland A, Shearer J, Coulter C, Caldwell M. Altered wound arginine metabolism by corticosterone and retinoic acid. J Surg Res 1997; 70:84-88.
32. Albina J, Mills C, Henry W, Caldwell M. Temporal expression of different pathways of L-arginine metabolism in healing wounds. J Immunol 1990; 144:3877-3880.
33. Cendan J, Topping D, Pruitt , Snowdy S, Copeland E, Lind S. Inflammatory mediators stimulate arginine transport and arginine-derived nitric oxide production in a murine breast cancer cell line. J Surg Res 1996; 60:284-288.
34. Heys S, Segar A, Payne S, Bruce D, Kernohan N, Eremin O. Dietary supplementation with L-arginine: modulation of tumour-infiltrating lymphocytes in patients with colorectal cancer. Br J Surg 1997; 84:238-241.
35. McCarter M, Gentilini O, Gomez M, Daly J. Preoperative oral supplement with immunonutrients in cancer patients. J Parenter Enter Nutr 1998; 22:206-211.
36. Cui S, Reichner J, Mateo R, Albina J. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or - independent mechanisms. Cancer Res 1994; 54:2462-2467.
37. Stuehr D, Nathan C. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169:1543-1555.
38. Farais-Eisner R, Sherman M, Aeberhard E, Chasudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A 1994; 91:9407-9411.
39. Edwards P, Topping M, Kontaridis B, Moldawer L, Copeland E, Lind D. Arginine-enhanced enteral nutrition augments the growth of a nitric oxide-producing tumor. J Parenter Enter Nutr 1997; 21:215-219.
40. Thomsen L, Scott J, Topley P, Knowles R, Keerie A, Frend A. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400 W, a novel inhibitor. Cancer Res 1997; 57:3300-3304.
41. Mills C, Shearer J, Evans R, Caldwell M. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 1992; 149:2709-2714.
42. Brittenden J, Heys S, Eremin O. L-arginine: biological aspects and clinical application. In: Immunological properties of L-arginine. Eremin O (editor). Austin, TX: RG Landes Co; 1997. pp. 27-78.
43. Packard B, Komoriya A. Tumor cell recognition by lymphocytes: is the MHC always essential? Crit Rev Immunol 1998; 18:139-144.
44. Barbul A, Lazarou S, Efron D, Wasserkrug H, Efron G. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 1990; 108:331-337.
45. Barbul A, Sisto D, Wasserkrug H, Efron G. Arginine stimulates lymphocyte immune response in healthy human beings. Surgery 1981; 90:244-251.
46. Barbul A, Fishel R, Shimzu S, Wasserkrug H, Yoshimura N, Tao R, Efron G. Intravenous hyperalimentation with high arginine levels improves wound healing and immune function. J Surg Res 1985; 38:328-334.
47. Barbul A, Wasserkrug H, Seifter E, Rettura G, Levenson S, Efron G. Immunostimulatory effects of arginine in normal and injured rats. J Surg Res 1980; 29:228-235.
48. Albina J, Henry W, Mastrofrancesco B, Martin B, Reichner J. Macrophage activation by culture in an anoxic environment. J Immunol 1995; 155:4391-4396.
49. Snell J, Chernyshev O, Gilbert D, Colton C. Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages. J Leukoc Biol 1997; 62:369-373.
50. Norris K, Schrimpf J, Flynn J, Morris S. Enhancement of macrophage microbicidal activity: supplemental arginine and citrulline augment nitric oxide production in murine macrophages and promote intracellular killing of Trypanosoma cruzi. Infect Immunol 1995; 63:2793-2796.
51. Miyagi K, Kawakami K, Saito A. Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei. Infect Immunol 1997; 65:4108-4113.
52. Silva J, Vespa G, Cardoso M, Aliberti J, Cunha F. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immunol 1995; 63:4682-4687.
53. Gross A, Spiesser S, Terraza A, Rouot B, Caron E, Dornand J. Expression and bactericidal activity of nitric oxide synthase in Brucella suis-infected murine macrophages. Infect Immunol 1998; 66:1309-1316.
54. Arias M, Rojas M, Zabaleta J, Rodreguez J, Paris S, Barrera L, Garcia L. Inhibition of virulent Mycobacterium tuberculosis by Bcg(r) and Bcg(s) macrophages correlates with nitric oxide production. J Infect Dis 1997; 176:1552-1558.
55. Sakiniene E, Bremell T, Tarkowski A. Inhibition of nitric oxide synthase (NOS) aggravates Staphylococcus aureus septicaemia and septic arthritis. Clin Exp Immunol 1997; 110:370-377.
56. Moffat F, Han T, Li Z, Peck M, Jy W, Ahn Y, et al. Supplemental L-arginine HCL augments bacterial phagocytosis in human polymorphonuclear leukocytes. J Cell Phys 1996; 168:26-33.
57. Sato H, Zhao Z, Vinten-Johansen J. L-arginine inhibits neutrophil adherence and coronary artery dysfunction. Cardiovasc Res 1996; 31:63-72.
58. McCall T, Palmer R, Boughton-Smith N, Whittle B, Moncada S. The L-arginine: nitric oxide pathway in neutrophils. In: Nitric oxide from L-arginine: a bioregulatory system. Moncada S, Higgs E (editors). New York: Elsevier Science; 1990. pp. 257-266.
59. Nath J, Prowledge A. Modulation of human neutrophil inflammatory responses by nitric oxide: studies in unprimed and LPS primed cells. J Leukoc Biol 1997; 62:805-816. This work provides further evidence of iNOS activity in polymorphonuclear cells.
60. Rodenas J, Mitjavila M, Carbonell T. Nitric oxide inhibits superoxide production by inflammatory polymorphonuclear leukocytes. Am J Physiol 1998; 274:C827-C830.
61. Efron D, Kirk S, Regan M, Wasserkrug H, Barbul A. Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis. Surgery 1991; 110:327-334.
62. Lander H, Sehajpal P, Levine D, Novogrodsky A. Activiation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol 1993; 150:1509-1516.
63. Wiebke E, Grieshop N, Sidner R, Howard T, Yang S. Effects of L-arginine supplementation on human lymphocyte proliferation in response to nonspecific and alloantigenic stimulation. J Surg Res 1997; 70:89-94. When given in vitro and at very high doses, arginine decreases T-cell mitogenic responses.
64. Schebesch C, Kodelja V, Muller C, Hakij N, Bisson S, Orfanos C, Goerdt S. Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology 1997; 92:478-486.
65. Fecho K, Maslonek K, Coussons-Read M, Dykstra L, Lysle D. Macrophage-derived nitric oxide is involved in the depressed concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. J Immunol 1994; 152:5845-5852.
66. Isobe K, Nakashima I. Nitric oxide production from a macrophage cell line: interaction with autologous and allogeneic lymphocytes. J Cell Biochem 1993; 53:198-205.
67. Isobe K, Nakashima I. Feedback suppression of staphylococcal enterotoxin-stimulated T-lymphocyte proliferation by macrophages through inductive nitric oxide synthesis. Infect Immunol 1992; 60:4832-4837.
68. Kawabe T, Isobe K, Hasegawa Y, Nakashima I, Shimokata K. Immunosuppressive activty induced by nitric oxide in culture supernatant of activated rat alveolar macrophages. Immunology 1992; 76:72-78.
69. Bingisser R, Tilbrook P, Holt P, Kees U. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/ STAT5 signalling pathway. J Immunol 1998; 160:5729-5734.
70. Benbernou N, Esnault S, Shin C, Fekkar H, Guenounou M. Differential regulation of INF-?, IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway. Immunology 1997; 91:361-368. Nitric oxide may provide its own self-regulation at an intracellular level but it also appears to influence differential cytokine production and, in turn, primary cellular function in T-cells. This has tremendous implications for the organization of the immune response, with the metabolism of arginine at the center.
71. Chang R, Lin Feng M, Liu W, Lai M. Nitric oxide increased interleukin-4 expression in T lymphocytes. Immunology 1997; 90:364-369.
72. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998; 160:5347-5354. The importance of understanding phenotypic variation of the immunomodulatory cells has become quite evident. The subpopulations of T-cells can drive macrophage phenotype and subsequent function.
73. Cueto E, Lopez-Herce J, Sanchez A, Carrillo A. Life-threatening effects of discontinuing inhaled nitric oxide in children. Acta Pediatr 1997; 86:1337-1339.
74. Dellinger R, Zimmerman J, Taylor R, Straube R, Hauser D, Criner G, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled nitric oxide in ARDS Study Group. Crit Care Med 1998; 26:15-23.
75. Johannigman J, Davis K, Campbell R, Luchette F, Hurst J, Branson R. Inhaled nitric oxide in acute respiratory distress syndrome. J Trauma 1997; 43:904-909.
76. Troncy E, Francoeur M, Blaise G. Inhaled nitric oxide: clinical applications, indications, and toxicology. Can J Anesth 1997; 44:973-988.
77. Fox-Robichaud A, Payne D, Hasan S, Ostrovsky L, Fairhead T, Reinhardt P, Kubes P. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998; 101:2497-2505.